Clinical Significance of Co-expression of Aberrant Antigens in Acute Leukemia
Seong-Hyun JEONG; Hyun-Woo LEE; Seok-Yun KANG; Mi-Sun AHN; Yoon-Ho HWANG; Jin-Hyuk CHOI; Hugh-Chul KIM; Sung-Ran CHO; Joon-Seong PARK; Seong-Hyun JEONG; Hyun-Woo LEE; Seok-Yun KANG; Mi-Sun AHN; Yoon-Ho HWANG; Jin-Hyuk CHOI; Hugh-Chul KIM; Sung-Ran CHO; Joon-Seong PARK.
Korean Journal of Hematology
; : 67-73, 2009.
Artículo
en Inglés
| WPRIM | ID: wpr-720425
BACKGROUND:
Acute leukemias co-expressing myeloid and lymphoid antigens but does not meet the criteria for biphenotypic acute leukemia (BAL) is common, however its clinical significance is not fully defined.METHODS:
In this study, clinical features of 68 co-expressing (myeloid and lymphoid) acute leukemias diagnosed between January 2000 and December 2006 were studied and compared with those of a control group of patients (pure AML or ALL).RESULTS:
Age, gender, initial Lactate dehydrogenase (LDH) level and cytogenetics were not different between the co-expressing group and the control group. But, the initial bone marrow blast percent was significantly higher in the co-expressing group (70% vs. 54.5%, P=0.003). Fifty five percent (16/29) of ALL and 30% (52/172) of AML patients showed myeloid and lymphoid markers concomitantly. The lymphoid antigen positive AML (Ly+AML) patients showed significantly shorter survival rates than pure AML patients (4 year survival rate, 17.6% vs. 45.6%, P=0.002). However hematopoietic stem cell transplantation (HST) abrogated the difference (4 year survival rate, 54.7% vs. 50.6%, P=0.894). In ALL patients, survival rate was not affected by myeloid antigen co-expression (4 year survival rate 26.1% vs. 20%, P=0.954).CONCLUSION:
Co-expression of lymphoid markers in AML should be regarded as a poor prognostic factor and more aggressive treatment such as HST should be considered.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados